Skip to main content
SpringerLink
Log in

Oxidative Stress in Autoimmune Liver Disease

  • Chapter
Studies on Hepatic Disorders

Abstract

Under normal physiological conditions, there is a balance between formation and removal of free radicals. However, when this equilibrium is broken secondary to increased formation of free radicals and/or reduced levels of antioxidants, the oxidative stress is present. Oxidative stress plays a major role in the development of chronic inflammatory and degenerative diseases such as cancer and autoimmune disorders. Increased oxidative stress has long been proposed as a unifying mechanism linking inflammation and fibrosis in autoimmune liver disease. Therefore, it suggests that antioxidant therapy could have a beneficial effect improving the inflammation and fibrosis. However, despite the promising results in cellular and animal models, only few clinical trials have demonstrated the beneficial effect of antioxidants on the prevention of progression of autoimmune liver disease. This chapter summarizes some of the relationships between oxidative stress and autoimmune liver disease pathogenesis and suggests antioxidant therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Medina J, Moreno-Otero R (2005) Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs 65(17):2445–2461

    Article  CAS  PubMed  Google Scholar 

  2. Albano E (2006) Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 65(3):278–290

    Article  CAS  PubMed  Google Scholar 

  3. Muriel P (2009) Role of free radicals in liver diseases. Hepatol Int 3(4):526–536

    Article  PubMed Central  PubMed  Google Scholar 

  4. Dryden GW, Deaciuc L, Arteel G, McClain CJ (2005) Clinical implications of oxidative stress and antioxidant therapy. Cur Gastroenterol Rep 7(4):308–316

    Article  Google Scholar 

  5. Schulze-Osthoff K, Haussinger D (2007) Apoptosis in the liver: a matter of ion fluxes and oxidative stress. Liver Int 27(8):1039–1044

    Article  PubMed  Google Scholar 

  6. Guimaraes EL, Franceschi MF, Grivicich I, Dal-Pizzol F, Moreira JC, Guaragna RM et al (2006) Relationship between oxidative stress levels and activation state on a hepatic stellate cell line. Liver Int 26:477–485

    Article  CAS  PubMed  Google Scholar 

  7. Sanz-Cameno P, Medina J, García-Buey L, García-Sánchez A, Borque MJ, Martín-Vílchez S et al (2002) Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. J Hepatol 37(6):723–729

    Article  CAS  PubMed  Google Scholar 

  8. Pemberton PW, Aboutwerat A, Smith A, Burrows PC, McMahon RF, Warnes TW (2004) Oxidant stress in type I autoimmune hepatitis: the link between necroinflammation and fibrogenesis? Biochim Biophys Acta 1689(3):182–189

    Article  CAS  PubMed  Google Scholar 

  9. Floreani A, Baragiotta A, Martines D, Naccarato R, D’odorica A et al (2000) Plasma antioxidants levels in chronic cholestasis liver disease. Aliment Pharmacol Ther 14(3):353–358

    Article  CAS  PubMed  Google Scholar 

  10. Medina J, Jones EA, García-Monzón C, Moreno-Otero R (2001) Immunopathogenesis of cholestatic autoimmune liver diseases. Eur J Clin Invest 31(1):64–71

    Article  CAS  PubMed  Google Scholar 

  11. Carbone M, Neuberger JM (2014) Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol 60(1):210–223

    Article  CAS  PubMed  Google Scholar 

  12. Rust C, Beuers U (2008) Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 14(21):3368–3373

    Article  PubMed Central  PubMed  Google Scholar 

  13. Abe M, Hiasa Y, Onji M (2013) T helper 17 cells in autoimmune liver diseases. Clin Dev Immunol 2013:607073. doi:10.1155/2013/607073

    Article  PubMed Central  PubMed  Google Scholar 

  14. Krawitt EL (2006) Autoimmune hepatitis. N Engl J Med 354(1):54–66

    Article  CAS  PubMed  Google Scholar 

  15. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D et al (2010) Diagnosis and management of autoimmune hepatitis. Hepatology 51(6):2193–2213

    Article  CAS  PubMed  Google Scholar 

  16. Mieli-Vergani T, Vergani D (2011) Autoimmune liver disease: news and perspectives. Transl Med UniSa 1:195–212

    PubMed Central  PubMed  Google Scholar 

  17. Yada N, Kudo M, Chung H, Watanabe T (2013) Autoimmune hepatitis and immunoglobulin G4-associated autoimmune hepatitis. Dig Dis 31(5–6):415–420

    Article  PubMed  Google Scholar 

  18. Hirschfield GM, Gershwin ME (2013) The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 8:303–330

    Article  CAS  PubMed  Google Scholar 

  19. Kim KA, Jeong SH (2011) The diagnosis and treatment of primary biliary cirrhosis. Korean J Hepatol 17(3):173–179

    Article  PubMed Central  PubMed  Google Scholar 

  20. Silveira MG, Lindor KD (2008) Primary sclerosing cholangitis. Can J Gastroenterol 22(8):689–698

    PubMed Central  PubMed  Google Scholar 

  21. Serviddio G, Pereda J, Pallardó FV, Carretero J, Borras C, Cutrin J et al (2004) Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 39(3):711–720

    Article  CAS  PubMed  Google Scholar 

  22. Marra F, Bertolini C (2008) Cellular and molecular mechanisms of hepatic fibrosis. Hematol Rev 5:10–17

    Google Scholar 

  23. Singal AK, Jampana SC, Weinman SA (2011) Antioxidants as therapeutic agents for liver disease. Liver Int 31(10):1432–1448

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C (2011) Antioxidant supplements for liver diseases. Cochrane Database Syst Rev (3):CD007749. doi:10.1002/14651858.CD007749.pub2

    Google Scholar 

  25. Prince MI, Mitchison HC, Ashley D, Burke DA, Edwards N, Bramble MG et al (2003) Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo controlled, cross-over trial. Aliment Pharmacol Ther 17(1):137–143

    Article  CAS  PubMed  Google Scholar 

  26. Czaja AJ, Carpenter HA, Lindor KD (1999) Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 30(6):1381–1386

    Article  CAS  PubMed  Google Scholar 

  27. Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A et al (2013) Review article: autoimmune hepatitis—current management and challenges. Aliment Pharmacol Ther 38(8):887–913

    Article  CAS  PubMed  Google Scholar 

  28. de Boer YS, van Gerven NM, de Boer NK, Mulder CJ, Bouma G, van Nieuwkerk CM (2013) Allopurinol safely and effectively optimizes thiopurine metabolites in patients with autoimmune hepatitis. Aliment Pharmacol Ther 37(6):640–646

    Article  PubMed  Google Scholar 

  29. Al-Shamma S, Eross B, Mclaughlin S (2013) Use of a xanthine oxidase inhibitor in autoimmune hepatitis. Hepatology 57(3):1281–1282

    Article  CAS  PubMed  Google Scholar 

  30. Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER (1996) Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 110(5):1515–1518

    Article  CAS  PubMed  Google Scholar 

  31. Yang YY, Huang YT, Lee KC, Lee FY, Lee TY, Hou MC (2009) Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis. Clin Sci (Lond) 116(1):71–79

    Article  CAS  Google Scholar 

  32. Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS (1986) A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 315(23):1448–1454

    Article  CAS  PubMed  Google Scholar 

  33. Kaplan MM, Cheng S, Price LL, Bonis PA (2004) A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 39(4):915–923

    Article  CAS  PubMed  Google Scholar 

  34. Leung J, Bonis P, Kaplan MM (2011) Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 9(9):776–780

    Article  CAS  PubMed  Google Scholar 

  35. Battezzati PM, Zuin M, Crosignani A, Allocca M, Invernizzi P, Selmi C (2001) Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment Pharmacol Ther 15(9):1427–1434

    Article  CAS  PubMed  Google Scholar 

  36. Trivedi PJ, Hirschfield GM (2013) Treatment of autoimmune liver disease: current and future therapeutic options. Ther Adv Chronic Dis 4(3):119–141

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Gong Y, Gluud C (2005) Colchicine for primary biliary cirrhosis: a Cochrane Hepato-Biliary Group systematic review of randomized clinical trials. Am J Gastroenterol 100(8):1876–1885

    Article  CAS  PubMed  Google Scholar 

  38. Kanda T, Yokosuka O, Imazeki F, Saisho H (2003) Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 38(6):573–578

    CAS  PubMed  Google Scholar 

  39. Levy C, Peter JA, Nelson DR, Keach J, Petz J, Cabrera R (2011) Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 33(2):235–242

    Article  CAS  PubMed  Google Scholar 

  40. Yano K, Kato H, Morita S, Takahara O, Ishibashi H, Furukawa R (2002) Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol 97(4):1075–1077

    Article  PubMed  Google Scholar 

  41. Kurihara T, Maeda A, Shigemoto M, Yamashita K, Hashimoto E (2002) Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol 97(1):212–214

    Article  PubMed  Google Scholar 

  42. Lindor KD (2011) Farnesoid X receptor agonists for primary biliary cirrhosis. Curr Opin Gastroenterol 27(3):285–288

    Article  CAS  PubMed  Google Scholar 

  43. Kowdley K, Jones D, Luketic V, Chapman R, Burroughs A, Hirschfield G et al (2011) An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol 54(Suppl):S13

    Article  Google Scholar 

  44. Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T (2009) Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice. Hepatology 49(6):1972–1981

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Lindor KD, Enders FB, Schmoll JA, Hoskin TL, Jorgensen RA, Petz JL et al (2008) Randomized, double-blind controlled trial of high-dose ursodeoxycholic acid (UDCA) for primary sclerosing cholangitis. Hepatology 48(Suppl):94A

    Google Scholar 

  46. Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK (2011) Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 34(8):901–910

    Article  CAS  PubMed  Google Scholar 

  47. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124(4):889–893

    Article  CAS  PubMed  Google Scholar 

  48. Lindström L, Boberg KM, Wikman O, Friis-Liby I, Hultcrantz R, Prytz H (2012) High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther 35(4):451–457

    Article  PubMed  Google Scholar 

  49. Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF (1991) The combination of prednisone and colchicine In patients with primary sclerosing cholangitis. Am J Gastroenterol 86(1):57–61

    CAS  PubMed  Google Scholar 

  50. Olsson R, Broomé U, Danielsson A, Hägerstrand I, Järnerot G, Lööf L et al (1995) Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 108(4):1199–1203

    Article  CAS  PubMed  Google Scholar 

  51. Tabibian JH, Lindor KD (2013) Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol 7(2):103–114

    Article  CAS  PubMed  Google Scholar 

  52. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD (2013) Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 145(3):521–536

    Article  CAS  PubMed  Google Scholar 

  53. Fickert P, Wagner M, Marschall HU, Fuchbichler A, Zollner G, Tsybrovskyy O (2006) 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130(2):465–481

    Article  CAS  PubMed  Google Scholar 

  54. Stanimirov B, Stankov K, Mikov M (2012) Pleiotropic functions of bile acids mediated by the farnesoid X receptor. Acta Gastroenterol Belg 75(4):389–398

    CAS  PubMed  Google Scholar 

  55. Lucena MI, Andrade RJ, de la Cruz JP, Rodriguez-Mendizabal M, Blanco E, Sanchez de la Cuesta F (2002) Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther 40(1):2–8

    Article  CAS  PubMed  Google Scholar 

  56. Bean P (2002) The use of alternative medicine in the treatment of hepatitis C. Am Clin Lab 21(4):19–21

    Google Scholar 

  57. Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N (2010) Multiple effects of silymarin on the hepatitis C virus life cycle. Hepatology 51(6):1912–1921

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD (2000) Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 32(5):897–900

    Article  CAS  PubMed  Google Scholar 

  59. Angulo P, Jorgensen RA, Kowdley KV, Lindor KD (2008) Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci 53(6):1716–1720

    Article  CAS  PubMed  Google Scholar 

  60. Mathes AM (2010) Hepatoprotective actions of melatonin: possible mediation by melatonin receptors. World J Gastroenterol 16(48):6087–6097

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Maestroni GJ (2001) The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 10(3):467–476

    Article  CAS  PubMed  Google Scholar 

  62. Martin C, Blanco P, Keach J, Petz J, Zaman M, Bhaskar K et al (2012) The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis—a pilot study. Aliment Pharmacol Ther 35(2):255–265

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD (2001) Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96(9):2711–2717

    Article  CAS  PubMed  Google Scholar 

  64. Moreno-Otero R (2013) May oxidative stress contribute to autoimmune hepatitis pathogenesis, and can antioxidants be of value as adjuvant therapy for refractory patients? Dig Dis Sci 58(5):1440–1441

    Article  PubMed  Google Scholar 

  65. Majano PL, Medina J, Zubía I, Sunyer L, Lara-Pezzi E, Maldonado-Rodríguez A et al (2004) N-Acetyl-cysteine modulates inducible nitric oxide synthase gene expression in human hepatocytes. J Hepatol 40(4):632–637

    Article  CAS  PubMed  Google Scholar 

  66. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR (1998) Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 95(4):1036–1042

    Google Scholar 

  67. Gong Y, Klingenberg SL, Gluud C (2006) Systematic review and meta-analysis: D-penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis—Cochrane Hepato-Biliary Group. Aliment Pharmacol Ther 24(11–12):1535–1544

    Article  CAS  PubMed  Google Scholar 

  68. Oo YH, Hubscher SG, Adams DH (2010) Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int 4(2):475–493

    Article  PubMed Central  PubMed  Google Scholar 

  69. Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD (2010) A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 95(9):2338–2342

    Article  Google Scholar 

  70. Okiyama W, Tanaka N, Nakajima T, Tanaka E, Kiyosawa K, Gonzalez FJ et al (2009) Polyenephosphatidylcholine prevents alcoholic liver disease in PPAR alpha-null mice through attenuation of increases in oxidative stress. J Hepatol 50(6):1236–1246

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  71. Smith RA, Murphy MP (2010) Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci 1201:96–103

    Article  CAS  PubMed  Google Scholar 

  72. Yuasa K, Naganuma A, Sato K, Ikeda M, Kato N, Takagi H et al (2006) Zinc is a negative regulator of hepatitis C virus RNA replication. Liver Int 26(9):1111–1118

    Article  CAS  PubMed  Google Scholar 

  73. Palioura S, Herkel J, Simonović M, Lohse AW, Söll D (2010) Human SepSecS or SLA/LP: selenocysteine formation and autoimmune hepatitis. Biol Chem 391(7):771–776

    Article  CAS  PubMed  Google Scholar 

  74. Czuczejko J, Zachara BA, Staubach-Topczewska E, Halota W, Kedziora J (2003) Selenium, glutathione and glutathione peroxidases in blood of patients with chronic liver diseases. Acta Biochim Pol 50(4):1147–1154

    CAS  PubMed  Google Scholar 

  75. Wang C, Nie H, Li K, Zhang YX, Yang F, Li CB et al (2012) Curcumin inhibits HMGB1 releasing and attenuates concanavalin A-induced hepatitis in mice. Eur J Pharmacol 697(1–3):152–157

    Article  CAS  PubMed  Google Scholar 

  76. Gupta SC, Kismali G, Aggarwal BB (2013) Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 39(1):2–13

    Article  CAS  PubMed  Google Scholar 

  77. Zingg JM (2007) Vitamin E: an overview of major research directions. Mol Aspects Med 28(5–6):400–422

    Article  CAS  PubMed  Google Scholar 

  78. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK et al (2004) A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2(12):1107–1115

    Article  CAS  PubMed  Google Scholar 

  79. von Herbay A, Stahl W, Niederau C, Sies H (1997) Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free Radic Res 27(6):599–605

    Article  Google Scholar 

  80. Abudu N, Miller JJ, Attaelmannan M, Levinson SS (2004) Vitamins in human arteriosclerosis with emphasis on vitamin C and vitamin E. Clin Chim Acta 339(1–2):11–25

    Article  CAS  PubMed  Google Scholar 

  81. Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C et al (2011) Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 55(2):388–398

    Article  CAS  PubMed  Google Scholar 

  82. Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL et al (2005) Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 5(5):1085–1089

    Article  PubMed  Google Scholar 

  83. Kita R, Kita-Sasai Y, Hanaoka I, Kimura T, Kokuryu H, Takamatsu S et al (2002) Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am J Gastroenterol 97(7):1849–1851

    Article  PubMed  Google Scholar 

  84. Luong KV, Nguyen LT (2013) The role of vitamin D in autoimmune hepatitis. J Clin Med Res 5(6):407–415

    PubMed Central  PubMed  Google Scholar 

  85. Smyk DS, Orfanidou T, Invernizzi P, Bogdanos DP, Lenzi M (2013) Vitamin D in autoimmune liver disease. Clin Res Hepatol Gastroenterol 37(5):535–545

    Article  CAS  PubMed  Google Scholar 

  86. Vogel A, Strassburg CP, Manns MP (2002) Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 35(1):126–131

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Digestive Diseases Service and Networked Biomedical Research Center for Hepatic and Digestive Diseases, Institute of Health Carlos III, Research Institute at La Princesa University Hospital, Autonomous university of Madrid, Diego de León 62, Madrid, 28006, Spain

    Verónica Martín-Domínguez, Eduardo Vilar-Gómez, Luisa García-Buey & Ricardo Moreno-Otero M.D.

Authors
  1. Verónica Martín-Domínguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eduardo Vilar-Gómez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luisa García-Buey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ricardo Moreno-Otero M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ricardo Moreno-Otero M.D. .

Editor information

Editors and Affiliations

  1. Department of Health Sciences, University of Eastern Piedmont Amedeo Avogadro, Novara, Italy

    Emanuele Albano

  2. Department of Clinical and Biological Sciences, Unit of Experimental Medicine and Clinical Pathology, School of Medicine, University of Torino, Torino, Italy

    Maurizio Parola

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Martín-Domínguez, V., Vilar-Gómez, E., García-Buey, L., Moreno-Otero, R. (2015). Oxidative Stress in Autoimmune Liver Disease. In: Albano, E., Parola, M. (eds) Studies on Hepatic Disorders. Oxidative Stress in Applied Basic Research and Clinical Practice. Humana Press, Cham. https://doi.org/10.1007/978-3-319-15539-5_14

Download citation

Publish with us

Policies and ethics

Search

Navigation